Today is Better Than Yesterday

By the end of yesterday, I was beyond stressed. Let's see why was I stressed: I have been feeling like crap because of the bump on my head. I have two friends in hospice care (see yesterday's blog). I have several other medical issues to deal with - my PCP keeps sending me with more blood tests to figure out why I have been so anemic (problem since chemo). My neck hurts from the (stupid) bone spur. My mother ended up in the emergency room yesterday (but she's going home today). I have my first craft show this weekend and need to get ready. I can't remember the rest.I was so stressed I was ready to call for an prescription of ativan (a/k/a lorazepam). But I survived.This morning I have taken my time to get ready for my upcoming craft fair. I have also talked to a friend and my mother. I feel slightly less stressed and am relaxing enough to get things done.I hate stress. I don't need any more medical issues. My mother needs to get healthier.
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: ailments craft fair friends stress Source Type: blogs

Related Links:

Authors: Park J PMID: 31915648 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
Abstract Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles may enhance efficacy. Dose-dense chemotherapy, which is adopted as adjuvant chemotherapy of high-risk breast cancer, is addressed in the Japanese Breast Cancer Society Clinical Practice Guideline for breast cancer, 2018 edition (in Japanese). To evaluate the benefits and safety of dose-dense adjuvant chemotherapy described in the guideline, we performed a systematic review and meta-analysis of data of randomized trials using the same drugs, doses, and numbers of cycles. The PubMed, Cochrane Library, and Ichushi-W...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news
Conclusions: Both the DL and DG regimens were associated with encouraging benefits, while treatment-related toxicity was manageable. Therefore, these regimens are effective options for treatment of rMBC. Trial registration: This clinical trial study was approved by the Ethics Committee of Guizhou Cancer Hospital, and has been registered in the China Clinical Trial Center (December 8, 2014, No. ChiCTR-IPR-14005633).
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
ttl J Abstract BACKGROUND: In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression-free survival (PFS) compared with physician's choice of chemotherapy (PCT) in germline BRCA1/2-mutated HER2-negative advanced breast cancer (ABC). Herein, the safety profile of talazoparib is explored in detail. MATERIALS AND METHODS: Overall, 412 patients received ≥1 dose of talazoparib (n = 286) or PCT (n = 126). Adverse events (AEs) were evaluated, including timing, duration, and potential overlap of selected AEs. The relationship between talazopari...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Publication date: Available online 11 November 2019Source: Blood Cells, Molecules, and DiseasesAuthor(s): Jana Volejnikova, Petr Vojta, Helena Urbankova, Renata Mojzíkova, Monika Horvathova, Ivana Hochova, Jaroslav Cermak, Jan Blatny, Martina Sukova, Eva Bubanska, Jaroslava Feketeova, Daniela Prochazkova, Julia Horakova, Marian Hajduch, Dagmar PospisilovaAbstractDiamond-Blackfan anemia (DBA) is a rare congenital erythroid aplasia, underlied by haploinsufficient mutations in genes coding for ribosomal proteins (RP) in approximately 70% of cases. DBA is frequently associated with somatic malformations, endocrine dysfu...
Source: Blood Cells, Molecules, and Diseases - Category: Hematology Source Type: research
ConclusionEmergency surgery is rare in breast cancer but should always be considered as an option when hemorrhage is not readily controlled.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Publication date: Available online 19 October 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Brittany Haynes, Ambikai Gajan, Pratima Nangia-Makker, Malathy P. ShekharAbstractTriple negative breast cancer (TNBC) is an aggressive breast cancer subtype with few therapy options besides chemotherapy. Although platinum-based drugs have shown initial activity in BRCA1-mutated TNBCs, chemoresistance remains a challenge. Here we show that RAD6B (UBE2B), a principal mediator of translesion synthesis (TLS), is overexpressed in BRCA1 wild-type and mutant TNBCs, and RAD6B overexpression correlate...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
ConclusionsThe exposure –response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher d ose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PD-L1 for TNBC...
Source: Oncology Reviews - Category: Cancer & Oncology Source Type: research
More News: Anemia | Ativan | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Emergency Medicine | Lorazepam